Cannabis stocks and ETFs have surged over the past few months since the Department of Health and Human Services asked the DEA to review its classification of cannabis. Earlier this month, a group of 12 state attorneys general sent a letter to the DEA supporting the reclassification.

Even though 24 states and Washington, D.C., have all legalized weed for recreational use, it remains illegal on the federal level. It is currently classified as a Schedule I drug, alongside heroin and LSD.

The new designation would place it in the same category as anabolic steroids, testosterone, and ketamine.

Cannabis companies currently face adverse taxation, lack access to the financial system, and their shares mostly trade over-the-counter or on Canadian exchanges.

Industry participants and investors were earlier hopeful for a more rapid path to full federal legalization under the Biden administration, but not much progress has been made so far.

The SAFER Banking Act, which would allow cannabis companies to use major financial and banking institutions, passed in the Senate Banking Committee in September, but its fate remains uncertain.

US cannabis companies, particularly multistate operators like Green Thumb Industries GTBIF, Curaleaf Holdings CURLF and Verano Holdings VRNOF, could be the biggest beneficiaries of any reform.

To learn about the AdvisorShares Pure US Cannabis ETF MSOS, the ETFMG U.S. Alternative Harvest ETF MJUS and the Roundhill Cannabis ETF WEED, please watch the short video above.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AdvisorShares Pure US Cannabis ETF (MSOS): ETF Research Reports

ETFMG U.S. Alternative Harvest ETF (MJUS): ETF Research Reports

Green Thumb Industries Inc. (GTBIF) : Free Stock Analysis Report

Verano Holdings Corp. (VRNOF) : Free Stock Analysis Report

Roundhill Cannabis ETF (WEED): ETF Research Reports

Curaleaf Holdings, Inc. (CURLF) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research